Coya Therapeutics, Inc.
A Houston-based biotech developing therapies that boost the body's regulatory T cells — the immune system's peacekeepers — to fight the inflammation behind neurodegenerative diseases like Parkinson's, Alzheimer's and ALS. Founder Dr. Howard Berman started the company in 2020 after his father's battle with dementia, teaming up with neurologist Dr. Stanley Appel. Its name echoes the earlier venture Berman co-founded, Nicoya Health.
Granted 17.6K
Bought 10.0K
Bought 1.8K
Bought 2.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Goldstein Dov A MDDirector · 1 transaction | +175.6% | 27.6Kas of Aug 2025 | 17.6K | — | — |
| Swaminathan ArunChief Executive Officer, Director · 2 transactions | — | 10.0Kas of Nov 2024 | — | 10.0K | — |
| Snyder David SChief Financial Officer · 1 transaction | +25.7% | 8.8Kas of Nov 2024 | — | 1.8K | — |
| Grossman FredChief Medical Officer · 1 transaction | — | 2.7Kas of Nov 2024 | — | 2.7K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: +14.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.